Smith Group Asset Management’s Phibro Animal Health PAHC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$798K Buy
25,407
+386
+2% +$16.3K 0.03% 118
2026
Q1
$1.38M Sell
25,021
-2,334
-9% -$111K 0.07% 76
2025
Q4
$1.02M Buy
27,355
+676
+3% +$27.5K 0.05% 91
2025
Q3
$1.08M Buy
26,679
+805
+3% +$26.6K 0.06% 88
2025
Q2
$661K Hold
25,874
0.04% 115
2025
Q1
$553K Buy
25,874
+99
+0.4% +$2.21K 0.04% 128
2024
Q4
$541K Buy
+25,775
New +$596K 0.04% 139
2019
Q2
Sell
-3,790
Closed -$125K 444
2019
Q1
$125K Sell
3,790
-11,900
-76% -$370K ﹤0.01% 245
2018
Q4
$505K Sell
15,690
-400
-2% -$15.1K 0.02% 191
2018
Q3
$690K Buy
+16,090
New +$760K 0.02% 188

Other funds holding PAHC

Smith Group Asset Management's PAHC Position: Q2 2026 in Review

Smith Group Asset Management increased its Phibro Animal Health (PAHC) stake by 1.5% in Q2 2026, buying an estimated $16.3K and bringing the position to 25,407 shares worth $798K. The position accounts for 0.03% of the portfolio, ranked #118.

Smith Group Asset Management first reported a position in PAHC in Q3 2018 and has held it in 10 quarters since. The position peaked at $1.38M in Q1 2026. 208 funds tracked by Wall St. Rank hold PAHC as of Q2 2026.

  • Smith Group Asset Management held 25,407 shares of Phibro Animal Health worth $798K as of Q2 2026.
  • Smith Group Asset Management bought 386 Phibro Animal Health shares in Q2 2026, an estimated $16.3K.
  • Phibro Animal Health made up 0.03% of Smith Group Asset Management's portfolio in Q2 2026, its #118 holding.
  • Smith Group Asset Management first reported a position in Phibro Animal Health in Q3 2018 and has held it in 10 quarters since.
  • Smith Group Asset Management's Phibro Animal Health position peaked at $1.38M in Q1 2026.
  • 208 funds tracked by Wall St. Rank held Phibro Animal Health as of Q2 2026.

Based on Smith Group Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.